{"gene":"SUCLG2","run_date":"2026-04-28T21:42:57","timeline":{"discoveries":[{"year":1998,"finding":"SUCLG2 encodes the GTP-specific beta subunit (G-beta) of succinyl-CoA synthetase. The ATP-specific (SUCLA2/A-beta) and GTP-specific (SUCLG2/G-beta) isoforms share the same alpha subunit but differ in their beta subunits, which are only ~53% identical. Both beta subunits were sequenced and confirmed by PCR across multiple mammalian species, establishing that two distinct succinyl-CoA synthetase isoenzymes exist in multicellular eukaryotes.","method":"Reverse transcription-PCR, sequence alignment, identification of expressed sequence tags","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — direct biochemical and molecular characterization, replicated across multiple species","pmids":["9765291"],"is_preprint":false},{"year":2004,"finding":"SUCLG2 (GDP-forming succinyl-CoA synthetase beta subunit) is expressed in mammalian tissues with tissue-specific variation in relative amounts compared to the ADP-forming isoform (SUCLA2). The GDP-forming enzyme containing SUCLG2 supports GTP-dependent anabolic processes, while the ADP-forming enzyme augments ATP production, and both catalyze the citric acid cycle reaction. Shuttle mechanisms were proposed to explain transfer of high-energy phosphate between the cytosol and mitochondrial matrix.","method":"Western blot, Northern blot, enzymatic assays across mammalian tissues","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — direct biochemical assays with enzymatic activity measurement across tissues","pmids":["15234968"],"is_preprint":false},{"year":2011,"finding":"SUCLG2 knockdown in human fibroblasts (including SUCLA2-deficient patient fibroblasts) caused significant decrease in mitochondrial DNA (mtDNA) content, decreased nucleoside diphosphate kinase (NDPK) activity, decreased cytochrome c oxidase activity, and marked growth impairment. This demonstrates that SUCLG2 is crucial for mtDNA maintenance through its association with mitochondrial NDPK, explaining how SUCL deficiency leads to mtDNA depletion syndrome.","method":"shRNA knockdown, mtDNA quantification, NDPK activity assay, cytochrome c oxidase activity assay, cell growth measurement","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 2 — clean KO with multiple defined cellular phenotypes and orthogonal enzymatic assays","pmids":["21295139"],"is_preprint":false},{"year":2014,"finding":"SUCLG2 protein localizes to the mitochondrial network in human fibroblasts (confirmed by co-localization with MitoTracker Orange) and is expressed in cells forming the cerebral microvasculature in human cortical tissue. SUCLG2 is absent from astroglia (GFAP+, S100+), microglia (Iba1+), and oligodendroglia (MBP+), consistent with the absence of matrix substrate-level phosphorylation in glial cells.","method":"Double immunofluorescence confocal microscopy, MitoTracker co-localization, in situ hybridization, Western blot","journal":"Journal of bioenergetics and biomembranes","confidence":"Medium","confidence_rationale":"Tier 2 — direct subcellular localization by imaging with cell-type specificity validated","pmids":["25370487"],"is_preprint":false},{"year":2018,"finding":"Mutation of the alpha subunit SUCLG1 (p.Ala209Glu) causes mislocalization of SUCLG2 protein — SUCLG2 co-localizes only partially with the mitochondrial network rather than fully, and SUCLG2 protein levels are greatly reduced. This is accompanied by impaired mitochondrial substrate-level phosphorylation, increased mitochondrial fragmentation, and mild mtDNA depletion, establishing that proper SUCLG1 is required for correct SUCLG2 mitochondrial localization and succinyl-CoA ligase complex integrity.","method":"Confocal immunocytochemistry (triple labeling), oxygen consumption assay, mitochondrial substrate-level phosphorylation measurement, immunoblot, mtDNA quantification","journal":"Molecular genetics and metabolism","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods in patient-derived cells with clear mechanistic link","pmids":["30470562"],"is_preprint":false},{"year":2020,"finding":"In prostate cancer cells, EGFR-LIFR signaling induces SUCLG2 expression downstream of androgen deprivation therapy. Nuclear EGFR acts as a transcriptional regulator binding the LIFR promoter, and LIFR upregulation drives SUCLG2 expression. SUCLG2 upregulation increases succinate synthesis and enhances mitochondrial NDPK enzymatic activity, promoting neuroendocrine differentiation and glycolysis. Knockdown of SUCLG2 suppressed neuroendocrine differentiation in cultured cells and reduced tumor growth in xenograft models.","method":"ChIP (EGFR binding to LIFR promoter), SUCLG2 knockdown, NDPK activity assay, xenograft tumor model, immunohistochemistry","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — pathway placement by epistasis with ChIP and enzymatic assay, supported by in vivo model","pmids":["32963351"],"is_preprint":false},{"year":2022,"finding":"Germline variants in the GTP-binding domain of SUCLG2 are found in pheochromocytoma/paraganglioma patients. SUCLG2-deficient tumor cells and hPheo1 cells with SUCLG2 ablation show absence of SUCLG2 protein, decreased SDHB subunit levels, faulty assembly of mitochondrial complex II (succinate dehydrogenase), aberrant respiration, and elevated succinate accumulation, establishing SUCLG2 as required for SDH complex II assembly and function.","method":"Genetic panel sequencing, SUCLG2 ablation and re-expression in hPheo1 cells, protein immunoblot (SDHB), respiratory assay, succinate measurement","journal":"Journal of the National Cancer Institute","confidence":"High","confidence_rationale":"Tier 2 — rescue experiment (ablation + re-expression), multiple orthogonal assays, patient tumor validation","pmids":["34415331"],"is_preprint":false},{"year":2023,"finding":"SUCLG2 controls the overall succinylation landscape in lung adenocarcinoma cells. Deletion of SUCLG2 upregulates succinylation of mitochondrial proteins, inhibiting key metabolic enzymes by reducing enzymatic activity or protein stability, thereby dampening mitochondrial function. SUCLG2 itself is succinylated at Lys93, which enhances its protein stability. SIRT5 desuccinylates SUCLG2 at Lys93, leading to TRIM21-mediated K63-linked ubiquitination and lysosomal degradation of SUCLG2.","method":"Succinylome mass spectrometry, SUCLG2 deletion, site-directed mutagenesis (Lys93), enzymatic activity assays, protein stability assays, SIRT5 knockdown/overexpression, Co-IP with TRIM21, ubiquitination assay, lysosome inhibitor treatment","journal":"Advanced science","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including succinylome proteomics, mutagenesis, and PTM writer/eraser identification","pmids":["37904651"],"is_preprint":false},{"year":2023,"finding":"Suclg2 maintains the tolerogenic phenotype of regulatory dendritic cells (diffDCs) by suppressing NF-κB signaling. Suclg2 inhibits succinylation of Lactb at lysine 288; without Suclg2, Lactb is succinylated and acts as a positive regulator of NF-κB signaling, promoting inflammatory gene expression (CD40, Ccl5, Il12b) and impairing T cell apoptosis induction.","method":"Suclg2 siRNA interference, NF-κB signaling assay, succinylation site identification (Lactb K288), metabolomic and transcriptomic profiling, functional immune assays","journal":"Journal of autoimmunity","confidence":"Medium","confidence_rationale":"Tier 2 — specific substrate modification identified with functional immune readout, single lab","pmids":["37216870"],"is_preprint":false},{"year":2025,"finding":"SUCLG2 interacts with LMNA (Lamin A/C), leading to acetylation of LMNA at K470 and affecting oxidative phosphorylation and mitochondrial integrity. SUCLG2 also interacts with DLAT, reducing H4K16la (lactylation) binding to gene promoters and cis-regulatory elements, thereby suppressing expression of BEST1, GRAMD4, and MBD6 and influencing GBM cell proliferation and apoptosis.","method":"Co-immunoprecipitation (SUCLG2-LMNA, SUCLG2-DLAT), acetylation and lactylation assays, ChIP, gene expression analysis, SUCLG2 knockdown with proliferation/apoptosis readouts","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2-3 — Co-IP binding partners identified with downstream PTM and functional phenotype, single lab","pmids":["41249152"],"is_preprint":false}],"current_model":"SUCLG2 encodes the GTP-forming beta subunit of mitochondrial succinyl-CoA ligase (SCS-G), which catalyzes succinyl-CoA to succinate conversion coupled to GTP synthesis in the TCA cycle; it forms a heterodimer with the SUCLG1 alpha subunit, requires proper SUCLG1 for mitochondrial localization, maintains mtDNA through functional coupling with mitochondrial NDPK, supports SDH (complex II) assembly, controls cellular succinylation homeostasis (with its own stability regulated by SIRT5-mediated desuccinylation at K93 and subsequent TRIM21-driven lysosomal degradation), and interacts with LMNA and DLAT to modulate epigenetic and metabolic reprogramming in cancer cells."},"narrative":{"teleology":[{"year":1998,"claim":"Identification of SUCLG2 as a distinct GTP-specific beta subunit established that two succinyl-CoA synthetase isoenzymes exist in multicellular eukaryotes, resolving why both GTP- and ATP-linked activities had been detected in mitochondria.","evidence":"RT-PCR cloning and sequence alignment across mammalian species","pmids":["9765291"],"confidence":"High","gaps":["No crystal structure of the GDP-forming heterodimer","Relative catalytic parameters of SUCLG2- versus SUCLA2-containing holoenzymes not yet determined"]},{"year":2004,"claim":"Tissue-level profiling showed that the SUCLG2 (GDP-forming) and SUCLA2 (ADP-forming) isoforms are differentially expressed across mammalian organs, indicating that tissue-specific TCA cycle tuning is achieved through beta-subunit selection.","evidence":"Western blot, Northern blot, and enzymatic activity assays across mammalian tissues","pmids":["15234968"],"confidence":"High","gaps":["Transcriptional regulators controlling isoform selection not identified","High-energy phosphate shuttling between matrix GTP and cytosolic ATP remained hypothetical"]},{"year":2011,"claim":"Knockdown of SUCLG2 revealed an unexpected extra-catalytic role: SUCLG2 is required for mtDNA maintenance through its association with mitochondrial NDPK, linking succinyl-CoA ligase deficiency to mtDNA depletion syndrome.","evidence":"shRNA knockdown in human fibroblasts with mtDNA quantification, NDPK activity assay, and cytochrome c oxidase activity measurement","pmids":["21295139"],"confidence":"High","gaps":["Direct physical interaction between SUCLG2 and mitochondrial NDPK not structurally characterized","Whether the NDPK-coupling mechanism differs between SUCLG2 and SUCLA2 isoforms was not resolved"]},{"year":2014,"claim":"Subcellular imaging confirmed SUCLG2 resides in the mitochondrial network and demonstrated cell-type-specific expression in human brain, with SUCLG2 present in cerebrovascular cells but absent from glia.","evidence":"Double immunofluorescence confocal microscopy with MitoTracker co-localization and in situ hybridization in human cortical tissue","pmids":["25370487"],"confidence":"Medium","gaps":["Functional consequence of glial absence of SUCLG2 not tested directly","Sub-mitochondrial localization (matrix vs. inner membrane association) not resolved"]},{"year":2018,"claim":"Analysis of a pathogenic SUCLG1 mutation showed that proper SUCLG1 is required for SUCLG2 mitochondrial targeting and protein stability, establishing the alpha subunit as a determinant of holoenzyme assembly and localization.","evidence":"Confocal triple-label immunocytochemistry, substrate-level phosphorylation assays, and mtDNA quantification in patient-derived fibroblasts","pmids":["30470562"],"confidence":"High","gaps":["Whether mislocalized SUCLG2 is degraded by cytoplasmic quality control was not addressed","Import pathway elements mediating SUCLG2 mitochondrial targeting unknown"]},{"year":2022,"claim":"Discovery that SUCLG2 loss leads to defective SDH (complex II) assembly, aberrant respiration, and succinate accumulation expanded SUCLG2's role beyond the TCA cycle reaction itself and linked germline SUCLG2 variants to pheochromocytoma/paraganglioma.","evidence":"SUCLG2 ablation and re-expression in hPheo1 cells, SDHB immunoblot, respiratory assays, succinate measurement, and patient tumor genetic sequencing","pmids":["34415331"],"confidence":"High","gaps":["Mechanism by which SUCLG2 supports SDHB stability or SDH assembly is unclear","Penetrance and genotype–phenotype correlation of SUCLG2 variants in PPGL not established in large cohorts"]},{"year":2023,"claim":"Succinylome profiling established SUCLG2 as a master regulator of mitochondrial protein succinylation, and identified a feedback loop in which SUCLG2 Lys93 succinylation stabilizes the protein while SIRT5-mediated desuccinylation triggers TRIM21-dependent ubiquitination and lysosomal degradation.","evidence":"Succinylome mass spectrometry, SUCLG2 deletion, K93 site-directed mutagenesis, Co-IP with TRIM21, ubiquitination assays, and lysosome inhibitor treatment in lung adenocarcinoma cells","pmids":["37904651"],"confidence":"High","gaps":["Whether succinylation at K93 regulates catalytic activity in addition to stability is untested","Generalizability of SIRT5-TRIM21 axis beyond lung adenocarcinoma not confirmed"]},{"year":2023,"claim":"In regulatory dendritic cells, SUCLG2 suppresses NF-κB signaling by preventing succinylation of Lactb at K288, revealing an immunomodulatory function linked to succinylation control.","evidence":"siRNA knockdown with NF-κB signaling assays, succinylation site identification on Lactb, metabolomic and transcriptomic profiling, and T cell apoptosis functional assays","pmids":["37216870"],"confidence":"Medium","gaps":["Whether SUCLG2 directly desuccinylates Lactb or acts indirectly through succinyl-CoA pool depletion is not determined","Replication in primary human dendritic cells lacking"]},{"year":2025,"claim":"Identification of LMNA and DLAT as SUCLG2 interaction partners connected SUCLG2 to histone lactylation-mediated transcriptional regulation and nuclear lamin acetylation in glioblastoma, suggesting roles beyond mitochondrial metabolism.","evidence":"Co-immunoprecipitation of SUCLG2 with LMNA and DLAT, acetylation and lactylation assays, ChIP, proliferation and apoptosis readouts in GBM cells","pmids":["41249152"],"confidence":"Medium","gaps":["SUCLG2-LMNA and SUCLG2-DLAT interactions lack reciprocal pull-down validation and structural characterization","Nuclear or cytoplasmic pool of SUCLG2 mediating these interactions is not defined","Findings are from a single lab and single cancer type"]},{"year":null,"claim":"Key unresolved questions include the structural basis of the GDP-forming holoenzyme, the mechanism by which SUCLG2 promotes SDH complex II assembly, whether SUCLG2 operates outside mitochondria under physiological conditions, and the clinical penetrance of germline SUCLG2 variants in tumor predisposition.","evidence":"","pmids":[],"confidence":"Low","gaps":["No high-resolution structure of SUCLG1-SUCLG2 heterodimer","Mechanism coupling SUCLG2 to SDH assembly unresolved","SUCLG2 extra-mitochondrial functions require independent confirmation"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[0,1,2]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[7,8]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[3,4]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,1,2,6,7]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[5,6]}],"complexes":["Succinyl-CoA ligase (GDP-forming) heterodimer (SUCLG1-SUCLG2)"],"partners":["SUCLG1","SIRT5","TRIM21","LMNA","DLAT"],"other_free_text":[]},"mechanistic_narrative":"SUCLG2 encodes the GTP-specific beta subunit of mitochondrial succinyl-CoA ligase (succinate–CoA ligase, GDP-forming), which heterodimerizes with the SUCLG1 alpha subunit to catalyze the reversible conversion of succinyl-CoA to succinate coupled with substrate-level GTP synthesis in the tricarboxylic acid cycle [PMID:9765291, PMID:15234968]. Beyond this core catalytic role, SUCLG2 is required for mitochondrial DNA maintenance through functional coupling with nucleoside diphosphate kinase, for proper assembly of succinate dehydrogenase (complex II), and for controlling the global protein succinylation landscape—its own stability being regulated by SIRT5-mediated desuccinylation at Lys93, which triggers TRIM21-dependent ubiquitination and lysosomal degradation [PMID:21295139, PMID:34415331, PMID:37904651]. Correct mitochondrial localization of SUCLG2 depends on an intact SUCLG1 alpha subunit, and tissue-specific expression of SUCLG2 versus the ATP-forming SUCLA2 isoform tunes the balance between GTP- and ATP-generating substrate-level phosphorylation [PMID:30470562, PMID:15234968]. Germline variants in SUCLG2 have been identified in pheochromocytoma/paraganglioma patients, where loss of SUCLG2 leads to defective complex II assembly, aberrant respiration, and succinate accumulation [PMID:34415331]."},"prefetch_data":{"uniprot":{"accession":"Q96I99","full_name":"Succinate--CoA ligase [GDP-forming] subunit beta, mitochondrial","aliases":["GTP-specific succinyl-CoA synthetase subunit beta","G-SCS","GTPSCS","Itaconyl--CoA ligase [GDP-forming] subunit beta","Malyl--CoA ligase [GDP-forming] subunit beta","Succinyl-CoA synthetase beta-G chain","SCS-betaG"],"length_aa":432,"mass_kda":46.5,"function":"GTP-specific succinyl-CoA synthetase functions in the citric acid cycle (TCA), coupling the hydrolysis of succinyl-CoA to the synthesis of GTP and thus represents the only step of substrate-level phosphorylation in the TCA (PubMed:40108300). The beta subunit provides nucleotide specificity of the enzyme and binds the substrate succinate, while the binding sites for coenzyme A and phosphate are found in the alpha subunit (By similarity). Also able to act as a GTP-specific itaconyl- and malyl-CoA synthetase (PubMed:40108300)","subcellular_location":"Mitochondrion","url":"https://www.uniprot.org/uniprotkb/Q96I99/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SUCLG2","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SUCLG2","total_profiled":1310},"omim":[{"mim_id":"611224","title":"SUCCINATE-CoA LIGASE, GDP/ADP-FORMING, SUBUNIT ALPHA; SUCLG1","url":"https://www.omim.org/entry/611224"},{"mim_id":"603922","title":"SUCCINATE-CoA LIGASE, GDP-FORMING, SUBUNIT BETA; SUCLG2","url":"https://www.omim.org/entry/603922"},{"mim_id":"245400","title":"MITOCHONDRIAL DNA DEPLETION SYNDROME 9 (ENCEPHALOMYOPATHIC TYPE WITH METHYLMALONIC ACIDURIA); MTDPS9","url":"https://www.omim.org/entry/245400"},{"mim_id":"100850","title":"ACONITASE 2; ACO2","url":"https://www.omim.org/entry/100850"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Mitochondria","reliability":"Approved"},{"location":"Plasma membrane","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"liver","ntpm":259.9}],"url":"https://www.proteinatlas.org/search/SUCLG2"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q96I99","domains":[{"cath_id":"3.30.1490.20","chopping":"59-145","consensus_level":"high","plddt":95.2954,"start":59,"end":145},{"cath_id":"3.30.470.20","chopping":"151-276","consensus_level":"high","plddt":96.3623,"start":151,"end":276},{"cath_id":"3.40.50.261","chopping":"285-429","consensus_level":"high","plddt":93.2236,"start":285,"end":429}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96I99","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q96I99-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q96I99-F1-predicted_aligned_error_v6.png","plddt_mean":89.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SUCLG2","jax_strain_url":"https://www.jax.org/strain/search?query=SUCLG2"},"sequence":{"accession":"Q96I99","fasta_url":"https://rest.uniprot.org/uniprotkb/Q96I99.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q96I99/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96I99"}},"corpus_meta":[{"pmid":"37904651","id":"PMC_37904651","title":"SUCLG2 Regulates Mitochondrial Dysfunction through Succinylation in Lung Adenocarcinoma.","date":"2023","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/37904651","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21295139","id":"PMC_21295139","title":"The interplay between SUCLA2, SUCLG2, and mitochondrial DNA depletion.","date":"2011","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/21295139","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32963351","id":"PMC_32963351","title":"EGFR-upregulated LIFR promotes SUCLG2-dependent castration resistance and neuroendocrine differentiation of prostate cancer.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32963351","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37658588","id":"PMC_37658588","title":"METTL3-stabilized super enhancers-lncRNA SUCLG2-AS1 mediates the formation of a long-range chromatin loop between enhancers and promoters of SOX2 in metastasis and radiosensitivity of nasopharyngeal carcinoma.","date":"2023","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37658588","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34415331","id":"PMC_34415331","title":"Germline SUCLG2 Variants in Patients With Pheochromocytoma and Paraganglioma.","date":"2022","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/34415331","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30470562","id":"PMC_30470562","title":"Mutated SUCLG1 causes mislocalization of SUCLG2 protein, morphological alterations of mitochondria and an early-onset severe neurometabolic disorder.","date":"2018","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/30470562","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37216870","id":"PMC_37216870","title":"Metabolic enzyme Suclg2 maintains tolerogenicity of regulatory dendritic cells diffDCs by suppressing Lactb succinylation.","date":"2023","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/37216870","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25370487","id":"PMC_25370487","title":"Localization of SUCLA2 and SUCLG2 subunits of succinyl CoA ligase within the cerebral cortex suggests the absence of matrix substrate-level phosphorylation in glial cells of the human brain.","date":"2014","source":"Journal of bioenergetics and biomembranes","url":"https://pubmed.ncbi.nlm.nih.gov/25370487","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38233760","id":"PMC_38233760","title":"Regulatory function and mechanism research for m6A modification WTAP via SUCLG2-AS1- miR-17-5p-JAK1 axis in AML.","date":"2024","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38233760","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40925894","id":"PMC_40925894","title":"CircPSD3 aggravates tumor progression by maintaining TCA cycle and mitochondrial function via regulating SUCLG2 in thyroid carcinoma.","date":"2025","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/40925894","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41249152","id":"PMC_41249152","title":"Knockdown of SUCLG2 inhibits glioblastoma proliferation and promotes apoptosis through LMNA acetylation and the mediation of H4K16la lactylation.","date":"2025","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/41249152","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.08.15.669572","title":"Hypobaric hypoxia drives citrate cycle reprogramming to suppress tumor progression","date":"2025-08-20","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.15.669572","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20881960","id":"PMC_20881960","title":"Hundreds of variants clustered in genomic loci and biological pathways affect human height.","date":"2010","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/20881960","citation_count":1451,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19615732","id":"PMC_19615732","title":"Defining the human deubiquitinating enzyme interaction landscape.","date":"2009","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/19615732","citation_count":1282,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24816252","id":"PMC_24816252","title":"An atlas of genetic influences on human blood metabolites.","date":"2014","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24816252","citation_count":1209,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939629","id":"PMC_22939629","title":"A census of human soluble protein complexes.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939629","citation_count":689,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18976975","id":"PMC_18976975","title":"Genome-scale RNAi screen for host factors required for HIV replication.","date":"2008","source":"Cell host & microbe","url":"https://pubmed.ncbi.nlm.nih.gov/18976975","citation_count":627,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22190034","id":"PMC_22190034","title":"Global landscape of HIV-human protein complexes.","date":"2011","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/22190034","citation_count":593,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26344197","id":"PMC_26344197","title":"Panorama of ancient metazoan macromolecular complexes.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26344197","citation_count":407,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34079125","id":"PMC_34079125","title":"A proximity-dependent biotinylation map of a human cell.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/34079125","citation_count":339,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21145461","id":"PMC_21145461","title":"Dynamics of cullin-RING ubiquitin ligase network revealed by systematic quantitative proteomics.","date":"2010","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/21145461","citation_count":318,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"31056398","id":"PMC_31056398","title":"Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality.","date":"2019","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/31056398","citation_count":298,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34800366","id":"PMC_34800366","title":"Quantitative high-confidence human mitochondrial proteome and its dynamics in cellular context.","date":"2021","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/34800366","citation_count":239,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26618866","id":"PMC_26618866","title":"∆F508 CFTR interactome remodelling promotes rescue of cystic fibrosis.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26618866","citation_count":209,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29568061","id":"PMC_29568061","title":"An AP-MS- and BioID-compatible MAC-tag enables comprehensive mapping of protein interactions and subcellular localizations.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29568061","citation_count":201,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"30833792","id":"PMC_30833792","title":"A protein-interaction network of interferon-stimulated genes extends the innate immune system landscape.","date":"2019","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30833792","citation_count":159,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18461144","id":"PMC_18461144","title":"Systematic identification of mRNAs recruited to argonaute 2 by specific microRNAs and corresponding changes in transcript abundance.","date":"2008","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/18461144","citation_count":148,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32877691","id":"PMC_32877691","title":"A High-Density Human Mitochondrial Proximity Interaction Network.","date":"2020","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/32877691","citation_count":148,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24606901","id":"PMC_24606901","title":"Cochaperone binding to LYR motifs confers specificity of iron sulfur cluster delivery.","date":"2014","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24606901","citation_count":133,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9765291","id":"PMC_9765291","title":"Genetic evidence for the expression of ATP- and GTP-specific succinyl-CoA synthetases in multicellular eucaryotes.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9765291","citation_count":133,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21081503","id":"PMC_21081503","title":"RioK1, a new interactor of protein arginine methyltransferase 5 (PRMT5), competes with pICln for binding and modulates PRMT5 complex composition and substrate specificity.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21081503","citation_count":131,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10471510","id":"PMC_10471510","title":"Ocular albinism: evidence for a defect in an intracellular signal transduction system.","date":"1999","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10471510","citation_count":116,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34349018","id":"PMC_34349018","title":"Protein interaction landscapes revealed by advanced in vivo cross-linking-mass spectrometry.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/34349018","citation_count":113,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15234968","id":"PMC_15234968","title":"Expression of two succinyl-CoA synthetases with different nucleotide specificities in mammalian tissues.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15234968","citation_count":110,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20379614","id":"PMC_20379614","title":"Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score.","date":"2010","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/20379614","citation_count":108,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":7342,"output_tokens":2169,"usd":0.02728},"stage2":{"model":"claude-opus-4-6","input_tokens":5450,"output_tokens":2287,"usd":0.126637},"total_usd":0.355266,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":19193,"output_tokens":2944,"usd":0.050869},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":6519,"output_tokens":2709,"usd":0.15048}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2023,\n      \"finding\": \"SUCLG2 controls overall succinylation levels in lung adenocarcinoma cells; its deletion upregulates succinylation of mitochondrial proteins, inhibiting key metabolic enzyme activity or stability and dampening mitochondrial function. SUCLG2 itself is succinylated on Lys93, which enhances its protein stability. SIRT5 desuccinylates SUCLG2 on Lys93, followed by TRIM21-mediated K63-linked ubiquitination and lysosomal degradation.\",\n      \"method\": \"Succinylome mass spectrometry, shRNA knockdown, site-directed mutagenesis (Lys93), co-immunoprecipitation, ubiquitination assay, lysosomal inhibition experiments\",\n      \"journal\": \"Advanced Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (succinylome MS, mutagenesis, Co-IP, ubiquitination assay) in a single study with rigorous controls\",\n      \"pmids\": [\"37904651\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"SUCLG2 is crucial for mitochondrial DNA (mtDNA) maintenance and mitochondrial nucleoside diphosphate kinase (NDPK) activity; shRNA knockdown of SUCLG2 in human fibroblasts caused significant decrease in mtDNA amount, decreased NDPK and cytochrome c oxidase activities, and marked growth impairment, placing SUCLG2 upstream of NDPK-dependent mtDNA maintenance.\",\n      \"method\": \"shRNA knockdown in patient-derived and control fibroblasts, mtDNA quantification, enzyme activity assays (NDPK, cytochrome c oxidase), growth assays\",\n      \"journal\": \"Biochimica et Biophysica Acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KD with multiple defined functional readouts (mtDNA, enzyme activities, growth), replicated in patient and control cells\",\n      \"pmids\": [\"21295139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"EGFR-LIFR signaling induces SUCLG2 expression in prostate cancer cells; nuclear EGFR acts as a transcriptional regulator binding the LIFR promoter, and LIFR upregulation is associated with SUCLG2, which increases succinate synthesis and enzymatic activities of mitochondrial NDPK, promoting neuroendocrine differentiation.\",\n      \"method\": \"ChIP (nuclear EGFR binding LIFR promoter), SUCLG2 knockdown in cultured cells and xenograft models, NDPK activity assay, metabolite measurement\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP, enzymatic assay, and in vivo xenograft, but pathway epistasis relies on correlative steps between EGFR, LIFR, and SUCLG2\",\n      \"pmids\": [\"32963351\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Loss of SUCLG2 (GTP-binding domain variants) leads to absence of SUCLG2 protein, decreased SDHB subunit levels, faulty assembly of mitochondrial complex II (SDH), aberrant respiration, and elevated succinate accumulation, identifying SUCLG2 as required for proper SDH/complex II assembly and function.\",\n      \"method\": \"SUCLG2 ablation and re-expression in hPheo1 progenitor cell line, protein immunoblot, succinate measurement, respiration assay\",\n      \"journal\": \"Journal of the National Cancer Institute\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — rescue experiment (ablation + re-expression) with multiple functional readouts, single lab\",\n      \"pmids\": [\"34415331\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SUCLG1 mutation causes mislocalization of SUCLG2 protein away from the mitochondrial network, loss of mitochondrial substrate-level phosphorylation, and mitochondrial fragmentation, demonstrating that SUCLG2 requires SUCLG1 for proper mitochondrial targeting and heterodimer function.\",\n      \"method\": \"Confocal immunocytochemistry (triple immunostaining with mitotracker), enzyme activity assay (mSLP), oxygen consumption measurement in patient skin fibroblasts\",\n      \"journal\": \"Molecular Genetics and Metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization imaging with functional consequence demonstrated in patient fibroblasts, single lab\",\n      \"pmids\": [\"30470562\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SUCLG2 is localized to mitochondria in human cortical tissue (co-localization with mitotracker in fibroblasts), and in the human brain is restricted to cells forming the cerebral vasculature, not neurons, astrocytes, microglia, or oligodendrocytes, indicating cell-type-specific substrate-level phosphorylation capacity.\",\n      \"method\": \"Double immunofluorescence, mitotracker co-localization, in situ hybridization, Western blotting of post-mortem human cortical tissue\",\n      \"journal\": \"Journal of Bioenergetics and Biomembranes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization by multiple immunostaining approaches in human tissue, but functional consequence is inferred rather than directly tested\",\n      \"pmids\": [\"25370487\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In regulatory dendritic cells, Suclg2 suppresses succinylation of Lactb at lysine 288, preventing NF-κB signaling activation and maintaining tolerogenic DC function; Suclg2 interference impaired tolerogenicity and enhanced NF-κB-driven inflammatory gene expression.\",\n      \"method\": \"Metabolomics, transcriptomics, shRNA interference, NF-κB signaling assay, succinylation site identification (Lactb K288), T cell apoptosis assay\",\n      \"journal\": \"Journal of Autoimmunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (metabolomics, transcriptomics, functional KD) with specific succinylation site identified, single lab\",\n      \"pmids\": [\"37216870\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SUCLG2 interacts with LMNA and promotes its acetylation at K470, affecting oxidative phosphorylation and mitochondrial integrity; SUCLG2 also interacts with DLAT, reducing binding of lactylation mark H4K16la to promoter regions of BEST1, GRAMD4, and MBD6, suppressing their expression and affecting GBM cell proliferation and apoptosis.\",\n      \"method\": \"Co-immunoprecipitation (SUCLG2-LMNA, SUCLG2-DLAT), acetylation site identification (K470), ChIP for H4K16la, SUCLG2 knockdown with proliferation/apoptosis assays\",\n      \"journal\": \"Cell Death Discovery\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — Co-IP and site identification but single lab, limited orthogonal validation of mechanism\",\n      \"pmids\": [\"41249152\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SUCLG2 encodes the GTP-forming beta subunit of succinyl-CoA ligase (a heterodimer with SUCLG1) in the mitochondrial matrix, where it catalyzes succinyl-CoA hydrolysis coupled to GTP synthesis, supports mitochondrial DNA maintenance via NDPK activity, controls cellular succinylation homeostasis (with SIRT5 as its desuccinylase and TRIM21 as its ubiquitin E3 ligase mediating lysosomal degradation), and is required for proper assembly and function of mitochondrial complex II (SDH), with cell-type-specific expression in the brain restricted to vascular cells.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"SUCLG2 encodes the GTP-specific beta subunit (G-beta) of succinyl-CoA synthetase. The ATP-specific (SUCLA2/A-beta) and GTP-specific (SUCLG2/G-beta) isoforms share the same alpha subunit but differ in their beta subunits, which are only ~53% identical. Both beta subunits were sequenced and confirmed by PCR across multiple mammalian species, establishing that two distinct succinyl-CoA synthetase isoenzymes exist in multicellular eukaryotes.\",\n      \"method\": \"Reverse transcription-PCR, sequence alignment, identification of expressed sequence tags\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct biochemical and molecular characterization, replicated across multiple species\",\n      \"pmids\": [\"9765291\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"SUCLG2 (GDP-forming succinyl-CoA synthetase beta subunit) is expressed in mammalian tissues with tissue-specific variation in relative amounts compared to the ADP-forming isoform (SUCLA2). The GDP-forming enzyme containing SUCLG2 supports GTP-dependent anabolic processes, while the ADP-forming enzyme augments ATP production, and both catalyze the citric acid cycle reaction. Shuttle mechanisms were proposed to explain transfer of high-energy phosphate between the cytosol and mitochondrial matrix.\",\n      \"method\": \"Western blot, Northern blot, enzymatic assays across mammalian tissues\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct biochemical assays with enzymatic activity measurement across tissues\",\n      \"pmids\": [\"15234968\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"SUCLG2 knockdown in human fibroblasts (including SUCLA2-deficient patient fibroblasts) caused significant decrease in mitochondrial DNA (mtDNA) content, decreased nucleoside diphosphate kinase (NDPK) activity, decreased cytochrome c oxidase activity, and marked growth impairment. This demonstrates that SUCLG2 is crucial for mtDNA maintenance through its association with mitochondrial NDPK, explaining how SUCL deficiency leads to mtDNA depletion syndrome.\",\n      \"method\": \"shRNA knockdown, mtDNA quantification, NDPK activity assay, cytochrome c oxidase activity assay, cell growth measurement\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with multiple defined cellular phenotypes and orthogonal enzymatic assays\",\n      \"pmids\": [\"21295139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SUCLG2 protein localizes to the mitochondrial network in human fibroblasts (confirmed by co-localization with MitoTracker Orange) and is expressed in cells forming the cerebral microvasculature in human cortical tissue. SUCLG2 is absent from astroglia (GFAP+, S100+), microglia (Iba1+), and oligodendroglia (MBP+), consistent with the absence of matrix substrate-level phosphorylation in glial cells.\",\n      \"method\": \"Double immunofluorescence confocal microscopy, MitoTracker co-localization, in situ hybridization, Western blot\",\n      \"journal\": \"Journal of bioenergetics and biomembranes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct subcellular localization by imaging with cell-type specificity validated\",\n      \"pmids\": [\"25370487\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Mutation of the alpha subunit SUCLG1 (p.Ala209Glu) causes mislocalization of SUCLG2 protein — SUCLG2 co-localizes only partially with the mitochondrial network rather than fully, and SUCLG2 protein levels are greatly reduced. This is accompanied by impaired mitochondrial substrate-level phosphorylation, increased mitochondrial fragmentation, and mild mtDNA depletion, establishing that proper SUCLG1 is required for correct SUCLG2 mitochondrial localization and succinyl-CoA ligase complex integrity.\",\n      \"method\": \"Confocal immunocytochemistry (triple labeling), oxygen consumption assay, mitochondrial substrate-level phosphorylation measurement, immunoblot, mtDNA quantification\",\n      \"journal\": \"Molecular genetics and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods in patient-derived cells with clear mechanistic link\",\n      \"pmids\": [\"30470562\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In prostate cancer cells, EGFR-LIFR signaling induces SUCLG2 expression downstream of androgen deprivation therapy. Nuclear EGFR acts as a transcriptional regulator binding the LIFR promoter, and LIFR upregulation drives SUCLG2 expression. SUCLG2 upregulation increases succinate synthesis and enhances mitochondrial NDPK enzymatic activity, promoting neuroendocrine differentiation and glycolysis. Knockdown of SUCLG2 suppressed neuroendocrine differentiation in cultured cells and reduced tumor growth in xenograft models.\",\n      \"method\": \"ChIP (EGFR binding to LIFR promoter), SUCLG2 knockdown, NDPK activity assay, xenograft tumor model, immunohistochemistry\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway placement by epistasis with ChIP and enzymatic assay, supported by in vivo model\",\n      \"pmids\": [\"32963351\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Germline variants in the GTP-binding domain of SUCLG2 are found in pheochromocytoma/paraganglioma patients. SUCLG2-deficient tumor cells and hPheo1 cells with SUCLG2 ablation show absence of SUCLG2 protein, decreased SDHB subunit levels, faulty assembly of mitochondrial complex II (succinate dehydrogenase), aberrant respiration, and elevated succinate accumulation, establishing SUCLG2 as required for SDH complex II assembly and function.\",\n      \"method\": \"Genetic panel sequencing, SUCLG2 ablation and re-expression in hPheo1 cells, protein immunoblot (SDHB), respiratory assay, succinate measurement\",\n      \"journal\": \"Journal of the National Cancer Institute\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — rescue experiment (ablation + re-expression), multiple orthogonal assays, patient tumor validation\",\n      \"pmids\": [\"34415331\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SUCLG2 controls the overall succinylation landscape in lung adenocarcinoma cells. Deletion of SUCLG2 upregulates succinylation of mitochondrial proteins, inhibiting key metabolic enzymes by reducing enzymatic activity or protein stability, thereby dampening mitochondrial function. SUCLG2 itself is succinylated at Lys93, which enhances its protein stability. SIRT5 desuccinylates SUCLG2 at Lys93, leading to TRIM21-mediated K63-linked ubiquitination and lysosomal degradation of SUCLG2.\",\n      \"method\": \"Succinylome mass spectrometry, SUCLG2 deletion, site-directed mutagenesis (Lys93), enzymatic activity assays, protein stability assays, SIRT5 knockdown/overexpression, Co-IP with TRIM21, ubiquitination assay, lysosome inhibitor treatment\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including succinylome proteomics, mutagenesis, and PTM writer/eraser identification\",\n      \"pmids\": [\"37904651\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Suclg2 maintains the tolerogenic phenotype of regulatory dendritic cells (diffDCs) by suppressing NF-κB signaling. Suclg2 inhibits succinylation of Lactb at lysine 288; without Suclg2, Lactb is succinylated and acts as a positive regulator of NF-κB signaling, promoting inflammatory gene expression (CD40, Ccl5, Il12b) and impairing T cell apoptosis induction.\",\n      \"method\": \"Suclg2 siRNA interference, NF-κB signaling assay, succinylation site identification (Lactb K288), metabolomic and transcriptomic profiling, functional immune assays\",\n      \"journal\": \"Journal of autoimmunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — specific substrate modification identified with functional immune readout, single lab\",\n      \"pmids\": [\"37216870\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SUCLG2 interacts with LMNA (Lamin A/C), leading to acetylation of LMNA at K470 and affecting oxidative phosphorylation and mitochondrial integrity. SUCLG2 also interacts with DLAT, reducing H4K16la (lactylation) binding to gene promoters and cis-regulatory elements, thereby suppressing expression of BEST1, GRAMD4, and MBD6 and influencing GBM cell proliferation and apoptosis.\",\n      \"method\": \"Co-immunoprecipitation (SUCLG2-LMNA, SUCLG2-DLAT), acetylation and lactylation assays, ChIP, gene expression analysis, SUCLG2 knockdown with proliferation/apoptosis readouts\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP binding partners identified with downstream PTM and functional phenotype, single lab\",\n      \"pmids\": [\"41249152\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SUCLG2 encodes the GTP-forming beta subunit of mitochondrial succinyl-CoA ligase (SCS-G), which catalyzes succinyl-CoA to succinate conversion coupled to GTP synthesis in the TCA cycle; it forms a heterodimer with the SUCLG1 alpha subunit, requires proper SUCLG1 for mitochondrial localization, maintains mtDNA through functional coupling with mitochondrial NDPK, supports SDH (complex II) assembly, controls cellular succinylation homeostasis (with its own stability regulated by SIRT5-mediated desuccinylation at K93 and subsequent TRIM21-driven lysosomal degradation), and interacts with LMNA and DLAT to modulate epigenetic and metabolic reprogramming in cancer cells.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"SUCLG2 encodes the GTP-forming beta subunit of mitochondrial succinyl-CoA ligase, functioning as a heterodimer with SUCLG1 to catalyze substrate-level phosphorylation in the TCA cycle while serving as a critical regulator of cellular succinylation homeostasis and mitochondrial DNA maintenance. Loss of SUCLG2 causes global upregulation of mitochondrial protein succinylation, impairing metabolic enzyme activity and mitochondrial function, and its own stability is regulated by succinylation at Lys93 (reversed by SIRT5), followed by TRIM21-mediated K63-linked ubiquitination and lysosomal degradation [PMID:37904651]. SUCLG2 is required for mitochondrial NDPK activity and mtDNA maintenance, as its knockdown depletes mtDNA and impairs cytochrome c oxidase activity [PMID:21295139], and it is additionally necessary for proper assembly and function of mitochondrial complex II (SDH), with its loss leading to SDHB depletion, aberrant respiration, and succinate accumulation [PMID:34415331]. In the human brain, SUCLG2 expression is restricted to cerebral vascular cells rather than neurons or glia, indicating cell-type-specific capacity for GTP-linked substrate-level phosphorylation [PMID:25370487].\",\n  \"teleology\": [\n    {\n      \"year\": 2011,\n      \"claim\": \"Establishing that SUCLG2 functions beyond TCA cycle catalysis by demonstrating its requirement for mtDNA maintenance and NDPK activity resolved how GTP-forming succinyl-CoA ligase connects to nucleotide metabolism and mitochondrial genome integrity.\",\n      \"evidence\": \"shRNA knockdown in human fibroblasts with mtDNA quantification, NDPK and cytochrome c oxidase activity assays, and growth assays\",\n      \"pmids\": [\"21295139\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct physical interaction between SUCLG2 and NDPK not demonstrated\", \"Whether mtDNA depletion is a direct consequence of reduced dNTP supply or an indirect metabolic effect remains unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defining the cell-type-specific expression of SUCLG2 in human brain — restricted to cerebral vascular cells — revealed that GTP-linked substrate-level phosphorylation capacity is not uniform across brain cell types, with implications for understanding differential metabolic vulnerability.\",\n      \"evidence\": \"Double immunofluorescence, mitotracker co-localization, in situ hybridization, and Western blotting of post-mortem human cortical tissue\",\n      \"pmids\": [\"25370487\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequences of vascular-restricted expression not directly tested\", \"Whether this expression pattern holds across brain regions and developmental stages is unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrating that SUCLG1 mutation causes SUCLG2 mislocalization away from mitochondria and loss of substrate-level phosphorylation established the obligate heterodimer relationship and showed that SUCLG2 requires its alpha subunit partner for proper mitochondrial targeting.\",\n      \"evidence\": \"Confocal immunocytochemistry with mitotracker, enzyme activity assays, and oxygen consumption measurement in patient fibroblasts\",\n      \"pmids\": [\"30470562\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether SUCLG2 possesses an independent mitochondrial targeting signal that is insufficient without SUCLG1 is unresolved\", \"Single patient cell line studied\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Linking EGFR-LIFR signaling to transcriptional induction of SUCLG2 in prostate cancer identified an upstream regulatory axis and connected SUCLG2's enzymatic output (succinate production, NDPK activity) to neuroendocrine differentiation.\",\n      \"evidence\": \"ChIP for nuclear EGFR binding the LIFR promoter, SUCLG2 knockdown in cultured cells and xenograft models, NDPK activity assay, metabolite measurement\",\n      \"pmids\": [\"32963351\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Epistasis between LIFR and SUCLG2 is partly correlative\", \"Direct transcriptional regulation of SUCLG2 by LIFR signaling not fully delineated\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealing that SUCLG2 loss causes SDHB depletion, faulty complex II assembly, aberrant respiration, and succinate accumulation established an unexpected role for SUCLG2 in SDH/complex II integrity beyond its canonical ligase function.\",\n      \"evidence\": \"SUCLG2 ablation and re-expression in hPheo1 progenitor cell line with immunoblot, succinate measurement, and respiration assay\",\n      \"pmids\": [\"34415331\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which SUCLG2 supports SDHB stability or complex II assembly is unknown\", \"Whether this reflects succinyl-CoA/succinate imbalance or a direct chaperone-like role is unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Comprehensive succinylome analysis established SUCLG2 as a master controller of mitochondrial protein succinylation, revealed its own post-translational regulation cycle (Lys93 succinylation stabilizes, SIRT5 desuccinylation triggers TRIM21-mediated K63 ubiquitination and lysosomal degradation), and connected succinylation homeostasis to metabolic enzyme function.\",\n      \"evidence\": \"Succinylome mass spectrometry, shRNA knockdown, Lys93 mutagenesis, co-immunoprecipitation, ubiquitination assay, lysosomal inhibition in lung adenocarcinoma cells\",\n      \"pmids\": [\"37904651\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How SUCLG2 enzymatic activity mechanistically suppresses global succinylation (via succinyl-CoA consumption) versus alternative mechanisms is not fully separated\", \"Whether this SIRT5-TRIM21 regulatory axis operates in non-cancer cells is untested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrating that SUCLG2 suppresses succinylation of Lactb at K288 to prevent NF-κB activation in regulatory dendritic cells extended its succinylation-regulatory role to immune tolerance, identifying a specific substrate-site pair through which SUCLG2 influences inflammatory signaling.\",\n      \"evidence\": \"Metabolomics, transcriptomics, shRNA interference, NF-κB signaling assay, succinylation site identification in tolerogenic dendritic cells\",\n      \"pmids\": [\"37216870\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether Lactb K288 succinylation directly activates NF-κB or acts through an intermediate is not resolved\", \"Findings from murine DCs; human relevance not confirmed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The mechanism by which SUCLG2 supports mitochondrial complex II assembly, whether through succinyl-CoA metabolism, direct protein interaction with SDH subunits, or another route, remains undefined. Structural determinants of the SUCLG1-SUCLG2 heterodimer relevant to substrate-level phosphorylation specificity and the full scope of SUCLG2's succinylation-regulatory targets across tissues are also unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of human SUCLG1-SUCLG2 heterodimer\", \"Direct interaction between SUCLG2 and SDH subunits not tested\", \"Tissue-specific succinylome consequences of SUCLG2 loss not mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [0, 1, 3]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [1, 4, 5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 2, 3]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"complexes\": [\n      \"Succinyl-CoA ligase (SUCLG1-SUCLG2 heterodimer)\"\n    ],\n    \"partners\": [\n      \"SUCLG1\",\n      \"SIRT5\",\n      \"TRIM21\",\n      \"SDHB\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"SUCLG2 encodes the GTP-specific beta subunit of mitochondrial succinyl-CoA ligase (succinate–CoA ligase, GDP-forming), which heterodimerizes with the SUCLG1 alpha subunit to catalyze the reversible conversion of succinyl-CoA to succinate coupled with substrate-level GTP synthesis in the tricarboxylic acid cycle [PMID:9765291, PMID:15234968]. Beyond this core catalytic role, SUCLG2 is required for mitochondrial DNA maintenance through functional coupling with nucleoside diphosphate kinase, for proper assembly of succinate dehydrogenase (complex II), and for controlling the global protein succinylation landscape—its own stability being regulated by SIRT5-mediated desuccinylation at Lys93, which triggers TRIM21-dependent ubiquitination and lysosomal degradation [PMID:21295139, PMID:34415331, PMID:37904651]. Correct mitochondrial localization of SUCLG2 depends on an intact SUCLG1 alpha subunit, and tissue-specific expression of SUCLG2 versus the ATP-forming SUCLA2 isoform tunes the balance between GTP- and ATP-generating substrate-level phosphorylation [PMID:30470562, PMID:15234968]. Germline variants in SUCLG2 have been identified in pheochromocytoma/paraganglioma patients, where loss of SUCLG2 leads to defective complex II assembly, aberrant respiration, and succinate accumulation [PMID:34415331].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Identification of SUCLG2 as a distinct GTP-specific beta subunit established that two succinyl-CoA synthetase isoenzymes exist in multicellular eukaryotes, resolving why both GTP- and ATP-linked activities had been detected in mitochondria.\",\n      \"evidence\": \"RT-PCR cloning and sequence alignment across mammalian species\",\n      \"pmids\": [\"9765291\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal structure of the GDP-forming heterodimer\", \"Relative catalytic parameters of SUCLG2- versus SUCLA2-containing holoenzymes not yet determined\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Tissue-level profiling showed that the SUCLG2 (GDP-forming) and SUCLA2 (ADP-forming) isoforms are differentially expressed across mammalian organs, indicating that tissue-specific TCA cycle tuning is achieved through beta-subunit selection.\",\n      \"evidence\": \"Western blot, Northern blot, and enzymatic activity assays across mammalian tissues\",\n      \"pmids\": [\"15234968\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcriptional regulators controlling isoform selection not identified\", \"High-energy phosphate shuttling between matrix GTP and cytosolic ATP remained hypothetical\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Knockdown of SUCLG2 revealed an unexpected extra-catalytic role: SUCLG2 is required for mtDNA maintenance through its association with mitochondrial NDPK, linking succinyl-CoA ligase deficiency to mtDNA depletion syndrome.\",\n      \"evidence\": \"shRNA knockdown in human fibroblasts with mtDNA quantification, NDPK activity assay, and cytochrome c oxidase activity measurement\",\n      \"pmids\": [\"21295139\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct physical interaction between SUCLG2 and mitochondrial NDPK not structurally characterized\", \"Whether the NDPK-coupling mechanism differs between SUCLG2 and SUCLA2 isoforms was not resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Subcellular imaging confirmed SUCLG2 resides in the mitochondrial network and demonstrated cell-type-specific expression in human brain, with SUCLG2 present in cerebrovascular cells but absent from glia.\",\n      \"evidence\": \"Double immunofluorescence confocal microscopy with MitoTracker co-localization and in situ hybridization in human cortical tissue\",\n      \"pmids\": [\"25370487\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of glial absence of SUCLG2 not tested directly\", \"Sub-mitochondrial localization (matrix vs. inner membrane association) not resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Analysis of a pathogenic SUCLG1 mutation showed that proper SUCLG1 is required for SUCLG2 mitochondrial targeting and protein stability, establishing the alpha subunit as a determinant of holoenzyme assembly and localization.\",\n      \"evidence\": \"Confocal triple-label immunocytochemistry, substrate-level phosphorylation assays, and mtDNA quantification in patient-derived fibroblasts\",\n      \"pmids\": [\"30470562\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether mislocalized SUCLG2 is degraded by cytoplasmic quality control was not addressed\", \"Import pathway elements mediating SUCLG2 mitochondrial targeting unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Discovery that SUCLG2 loss leads to defective SDH (complex II) assembly, aberrant respiration, and succinate accumulation expanded SUCLG2's role beyond the TCA cycle reaction itself and linked germline SUCLG2 variants to pheochromocytoma/paraganglioma.\",\n      \"evidence\": \"SUCLG2 ablation and re-expression in hPheo1 cells, SDHB immunoblot, respiratory assays, succinate measurement, and patient tumor genetic sequencing\",\n      \"pmids\": [\"34415331\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which SUCLG2 supports SDHB stability or SDH assembly is unclear\", \"Penetrance and genotype–phenotype correlation of SUCLG2 variants in PPGL not established in large cohorts\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Succinylome profiling established SUCLG2 as a master regulator of mitochondrial protein succinylation, and identified a feedback loop in which SUCLG2 Lys93 succinylation stabilizes the protein while SIRT5-mediated desuccinylation triggers TRIM21-dependent ubiquitination and lysosomal degradation.\",\n      \"evidence\": \"Succinylome mass spectrometry, SUCLG2 deletion, K93 site-directed mutagenesis, Co-IP with TRIM21, ubiquitination assays, and lysosome inhibitor treatment in lung adenocarcinoma cells\",\n      \"pmids\": [\"37904651\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether succinylation at K93 regulates catalytic activity in addition to stability is untested\", \"Generalizability of SIRT5-TRIM21 axis beyond lung adenocarcinoma not confirmed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"In regulatory dendritic cells, SUCLG2 suppresses NF-κB signaling by preventing succinylation of Lactb at K288, revealing an immunomodulatory function linked to succinylation control.\",\n      \"evidence\": \"siRNA knockdown with NF-κB signaling assays, succinylation site identification on Lactb, metabolomic and transcriptomic profiling, and T cell apoptosis functional assays\",\n      \"pmids\": [\"37216870\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether SUCLG2 directly desuccinylates Lactb or acts indirectly through succinyl-CoA pool depletion is not determined\", \"Replication in primary human dendritic cells lacking\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identification of LMNA and DLAT as SUCLG2 interaction partners connected SUCLG2 to histone lactylation-mediated transcriptional regulation and nuclear lamin acetylation in glioblastoma, suggesting roles beyond mitochondrial metabolism.\",\n      \"evidence\": \"Co-immunoprecipitation of SUCLG2 with LMNA and DLAT, acetylation and lactylation assays, ChIP, proliferation and apoptosis readouts in GBM cells\",\n      \"pmids\": [\"41249152\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"SUCLG2-LMNA and SUCLG2-DLAT interactions lack reciprocal pull-down validation and structural characterization\", \"Nuclear or cytoplasmic pool of SUCLG2 mediating these interactions is not defined\", \"Findings are from a single lab and single cancer type\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of the GDP-forming holoenzyme, the mechanism by which SUCLG2 promotes SDH complex II assembly, whether SUCLG2 operates outside mitochondria under physiological conditions, and the clinical penetrance of germline SUCLG2 variants in tumor predisposition.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No high-resolution structure of SUCLG1-SUCLG2 heterodimer\", \"Mechanism coupling SUCLG2 to SDH assembly unresolved\", \"SUCLG2 extra-mitochondrial functions require independent confirmation\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [0, 1, 2]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [7, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [3, 4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 2, 6, 7]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [5, 6]}\n    ],\n    \"complexes\": [\n      \"Succinyl-CoA ligase (GDP-forming) heterodimer (SUCLG1-SUCLG2)\"\n    ],\n    \"partners\": [\n      \"SUCLG1\",\n      \"SIRT5\",\n      \"TRIM21\",\n      \"LMNA\",\n      \"DLAT\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}